Grifols voluntarily discloses transfers of value
- In line with its longstanding commitment to transparency, Grifols has disclosed, for the second consecutive year, all of its payments and other transfers of value to health professionals and health sector organizations in 33 European countries, including Spain.
- Grifols' transfers of value in Spain in 2016 totaled Euros 5.25 million, compared to Euros 9.55 million in 2015, representing a 45% year-on-year decrease.
- The transfers of value derived from R&D activities in Spain exceeded Euros 4 million in 2016. This represents nearly half of all transfers of value related to R&D initiatives realized by the Group in Europe.
- In 2016, Grifols made transfers of value in Spain to 426 healthcare professionals that totaled Euros 459,839 (-18% compared to 2015) and to 62 healthcare organizations that totaled Euros 762,418 (-3.5% compared to 2015).
- The Code of Conduct on Industry Interactions with Healthcare Professionals and Healthcare Organizations of the European Federation of Pharmaceutical Industries and Associations (EFPIA) applies specifically to medicines. Nonetheless, Grifols opted to expand its scope of application to include transfers unrelated to medications, as well as to the company's three divisions: Bioscience, Diagnostic and Hospital.
- Grifols applies this transparency policy in the United States as required by the regulatory body (Centers for Medicaid and Medicare Services, or CMS) and, in addition to Europe, also plans to implement it in countries such as Australia and Japan.
- All the information is available on the Grifols' corporate website: www.grifols.com
Information Published in Accordance to the EFPIA Code of Conduct
Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and health sector organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.
Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated on their behalf to manage the event; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities; and payments and other transfers of value related to R&D activities.
Specifically, the code of conduct is applied in the following European countries: France, Portugal, Slovakia, Denmark, Estonia, Germany, Italy, United Kingdom, Spain, Czech Republic, Ireland, Poland, Sweden, Switzerland, Belgium, Bulgaria, Croatia, Cyprus, Finland, Greece, Hungary, Latvia, Lithuania, Malta, the Netherlands, Norway, Romania, Russia, Serbia, Slovenia, Turkey and Ukraine.